Zimmer Biomet Reports Strong Financial Growth for Q3 2026 Despite EPS Drop

Zimmer Biomet's Third Quarter 2026 Financial Results: A Closer Look

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) proudly announced its financial performance for the third quarter ended September 30, 2026. The company reported net sales of $2.063 billion for the quarter, representing a solid increase of 3.1% on a reported basis and 3.7% when considering constant currency adjustments.

Financial Highlights

Despite the positive sales growth, the firm faced a 13.8% decline in diluted earnings per share, which stood at $1.00. However, when adjusted to account for various factors, the adjusted diluted earnings per share remained stable at $1.90, consistent with the previous year. Zimmer Biomet's operating cash flows reached an impressive $560.0 million, complemented by free cash flow of $372.4 million during the quarter.

Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet, expressed satisfaction with the company's performance, citing strong sales growth driven by successful product lines in Hips, S.E.T. (Sports Medicine, Biologics, Foot and Ankle, Upper Extremities, Trauma), as well as advancements in technology and surgical solutions. He stated, "Our diversification strategy and innovation engine are paying off, and we are proud of the metrics demonstrating our ongoing commercial success."

Business Developments

In addition to the financial results, Zimmer Biomet made noteworthy announcements, including the promotion of Gary Campbell, Brian Hatcher, and Bradley Kessler, aimed at further enhancing commercial transformation within the U.S. market.

The company also reaffirmed its commitment to robotics by extending a multi-year distribution and supply agreement with THINK Surgical. Recognized for its corporate excellence, Zimmer Biomet was included in TIME's 2026 World's Best Companies, highlighting their innovation and employee-focused practices.

Furthermore, Zimmer Biomet opened a new Institute in Charlotte, North Carolina, providing enhanced training in joint replacement and robotics to surgeons across the eastern U.S. This facility marks a significant step in reinforcing the company's commitment to advancing medical education.

The introduction of new products, such as the Megalodon® Dynamic Compression System and SmartShot® Marrow Access Device, reflects Zimmer Biomet's continuous effort to innovate in the medical technology landscape.

Financial Guidance and Future Outlook

The company also updated its full-year 2026 financial guidance, projecting an increase in reported revenue of 4.4% to 4.9%, alongside anticipated strong organic constant currency growth of 3.0% to 3.5%. For adjusted diluted earnings per share, the forecast has adjusted to between $8.50 and $8.60.

In conclusion, Zimmer Biomet's third quarter results demonstrate resilience and strategic growth, laying a solid foundation for future performance. As the company continues to evolve, its innovative solutions and commitment to excellence position it well for long-term success in the medical technology industry.

For more information regarding Zimmer Biomet’s financial results and corporate updates, please visit Zimmer Biomet's Investor Relations site.